Glycopeptides obtained after pronase digestion of normal rat hepatocytes and Zajdela hepatoma cells after 3H-mannose or 3H-glucosamine incorporation were compared. In both cell types, the glycopeptides were resolved in four peaks after gel filtration on Biogel P6 with a different distribution of radioactivity in normal and tumoral cells. The first peak (I) contained high molecular weight glycopeptides, and particularly a megaloglycopeptide (MW 70,000) exclusively present in malignant cells. Peaks II and III contained only N-linked glycopeptides but the ratio bi-antennary/tri-tetra-antennary glycopeptides was very different in normal and malignant cells. Only polymannosidic oligosaccharides were detected in peak IV and their amount was more important in normal than in malignant cells. These results are discussed in relation with the differentiation state of hepatic cells.

Download full-text PDF

Source

Publication Analysis

Top Keywords

malignant cells
12
glycopeptides normal
8
cells
8
hepatoma cells
8
normal malignant
8
glycopeptides
6
normal
5
[comparative analysis
4
analysis glycopeptides
4
normal liver
4

Similar Publications

Extracellular vesicles-a new player in the development of urinary bladder cancer.

Ther Adv Med Oncol

January 2025

Chair of Urology and Andrology, Department of Regenerative Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.

Bladder cancer was the 10th most commonly diagnosed cancer worldwide in 2020. Extracellular vesicles (EVs) are nano-sized membranous structures secreted by all types of cells into the extracellular space. EVs can transport proteins, lipids, or nucleic acids to specific target cells.

View Article and Find Full Text PDF

Chimeric Antigen Receptor (CAR)-T cell therapy has rapidly emerged as a groundbreaking approach in cancer treatment, particularly for hematologic malignancies. However, the application of CAR-T cell therapy in solid tumors remains challenging. This review summarized the development of CAR-T technologies, emphasized the challenges and solutions in CAR-T cell therapy for solid tumors.

View Article and Find Full Text PDF

Background: Dysbiosis of the lung microbiome can contribute to the initiation and progression of lung cancer. Synchronous multiple primary lung cancer (sMPLC) is an increasingly recognized subtype of lung cancer characterized by high morbidity, difficulties in early detection, poor prognosis, and substantial clinical challenges. However, the relationship between sMPLC pathogenesis and changes in the lung microbiome remains unclear.

View Article and Find Full Text PDF

Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer.

Front Immunol

January 2025

Department of Hematology and Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Immune dysfunction is one of the hallmarks of cancer and plays critical roles in immunotherapy resistance, but there is no serum biomarker that can be used to evaluate immune-dysfunction status of cancer patients. Here, we identified subtype-specific human endogenous retrovirus K102 envelope (HERV-K102-Env) with immunosuppressive activity in circulating blood as a novel serum immunosuppressive biomarker of cancer. We first generated monoclonal antibodies against K102-Env with high sensitivity and specificity, and we developed an ELISA assay to detect serum K102-Env.

View Article and Find Full Text PDF

Today, cancer has become one of the leading global tragedies. It occurs when a small number of cells in the body mutate, causing some of them to evade the body's immune system and proliferate uncontrollably. Even more irritating is the fact that patients with cancers frequently relapse after conventional chemotherapy and radiotherapy, leading to additional suffering.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!